Interpace Story

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;'>ID</div>
IDXG -- USA Stock  

USD 3.25  0.67  17.09%

Interpace Diagnostics is scheduled to announce its earnings today. The upcoming quarterly report is expected on the 28th of April 2021. As many retail investors are getting excited about healthcare space, it is fair to digest Interpace Diagnostics Group outlook under the latest economic conditions. We will analyze why it could be a much better year for Interpace Diagnostics shareholders.
Published over a month ago
View all stories for Interpace Diag | View All Stories
Our latest take on Interpace (NASDAQ:IDXG) analyst consensus
Interpace Diagnostics is UNDERVALUED at 5.81 per share with modest projections ahead. We provide advice to complement the regular expert consensus on Interpace Diagnostics. Our dynamic recommendation engine utilizes a multidimensional algorithm to analyze the company's potential to grow using all technical and fundamental data available at the time.
What is the right price you would pay to acquire a share of Interpace Diag? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated.
Please read more on our stock advisor page.

What is happening with Interpace Diag Group this year

Annual and quarterly reports issued by Interpace Diag Group are formal financial statements that are published yearly and quarterly and sent to Interpace stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934.
Companies such as Interpace Diag often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Interpace utilizes its cash?

To perform a cash flow analysis of Interpace Diag, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Interpace Diag is receiving and how much cash it distributes out in a given period. The Interpace Diag cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
Interpace Diag Net Cash Flow from Operations is projected to decrease significantly based on the last few years of reporting. The past year's Net Cash Flow from Operations was at (17.06 Million)

Is Interpace a risky opportunity?

Let's check the volatility. Interpace is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Interpace (NASDAQ:IDXG) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. purchasing a share of an Interpace Diagnostics stock makes you a part-owner of that company.

Interpace Diagnostics Group Current Consensus

Here is the latest trade recommendation based on an ongoing consensus estimate among financial analysis covering Interpace Diagnostics. The Interpace consensus assessment is calculated by taking the average estimates from all of the analysts covering Interpace Diagnostics

Strong Buy
Strong Buy3100.0
Strong Sell00.0

Interpace Diagnostics implied volatility may change after the dip

Variance is down to 28.69. It may indicate a possible volatility dip. Interpace Diagnostics Group exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate Interpace Diagnostics Group individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about Interpace Diagnostics future systematic risk.

Our Bottom Line On Interpace Diagnostics

Although many other companies within the diagnostics & research industry are still a little expensive, even after the recent corrections, Interpace Diagnostics may offer a potential longer-term growth to shareholders. In closing, as of the 21st of January 2021, we believe that at this point, Interpace Diagnostics is undervalued with high probability of financial unrest within the next 2 years. However, our up-to-date buy-hold-sell advice on the firm is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Interpace Diag Group. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to